BJP-2000-BECH-421-8

50 084 069102 usa trials v tca 047 036061 127 088182

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: is significantly superior to placebo and equal to tricyclic antidepressants (TCAs). & USA 5 USA 15 USA 16 In clinical terms fluoxetine had an15^20% improvement advantage to placebo which was maintained in the core symptoms of depression on the Hamilton Rating Scale. & Total [95% CI] 70.303 [70.393 to 70.213] 72 71.5 71 70.5 0 Fluoxetine better 0.5 Placebo better The discontinuation rate of fluoxetine due to adverse drug events was significantly lower than withTCAs. & Fig. 1 Effect size analysis for the actual change from baseline to end-point on the 17 item Hamilton Depression Rating Scale in seven USA trials v. placebo (all randomised patients analysed, using a last observation carried forward technique).The horizontal lines represent the result for each trial and the global estimate is given at the bottom of a graph. LIMITATIONS The meta-analysis criterion of DSM^III major depression excluded a rather high proportion of the European trials. & The trials were insufficient for evaluating the relationship between dose of fluoxetine and clinical response. & The USA trials have used older referenceTCAs whereas the European trials used newerTCAs. & USA 6 USA 7 USA 8 USA 9 USA 10 USA 11 USA 12 USA 13 USA 14 USA 15 USA 16 Subtotal [95% CI] Non-USA 1 Non-USA 2 Non-USA 3 Non-USA 4 Non-USA 5 Non-USA 6 Non-USA 7 Non-USA 8 Non-USA 9 Non-USA 11 Non-USA 12 Non-USA 13 Non-USA 14 Subtotal [95% CI] Total [95% CI] 70.002 [70.180 to 0.104] Correspondence: Dr P. Bech, Psychiatric Research Unit, Frederiksborg General Hospital, Dyrehavevej 48, DK ^34 00 Hilleroed, Denmark 00 (First received 22 June 1998, final revision 18 October 1999, accepted 18 October 1999) 0.171 [0.007 to 0.335] 0.049 [70.040 to 0.138] 71.5 71.0 7 0.5 0 0.5 1.0 1.5 2.0 Fluoxetine better Fig. 2 P. BECH, MD, Frederiksborg General Hospital, Hilleroed, Denmark; P. CIALDELLA, MD, M. C. HAUGH, PhD, A. HOURS, MD, J. P. BOISSEL, MD, Service de Pharmacologie Clinique, Lyon, France; M. A. BIRKETT, BSc,...
View Full Document

This note was uploaded on 01/16/2013 for the course BMS 620 taught by Professor Panavalil during the Summer '12 term at Barry Univesity.

Ask a homework question - tutors are online